Macrovascular Outcomes There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with semaglutide
GLP-1 receptor agonists are approved for conditions such as Type 2 diabetes and certain weight-related indications, not for addiction treatment
For extrapolation beyond 48 weeks, the GLP-1 and GIP receptor mechanisms are the most relevant reference points, and Semaglutide has now been tracked in millions of patients for 7-plus years with no catastrophic late-emerging safety events
NSAIDs have shown a relatively clear positive effect in reducing the incidence of postoperative delirium
This historical trajectory strongly suggests that GLP-1 should not be viewed as an isolated success, but rather as a prototype for a much larger class of peptidereceptor systems whose translational potential remains unrealized
Diet, exercise, sleep, and stress management all influence treatment outcomes and can modify the answer to this question for your specific situation
